天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>315703-52-7

315703-52-7

中文名稱 N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
英文名稱 N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-amine
CAS 315703-52-7
分子式 C19H18N4OS
分子量 350.44
MOL 文件 315703-52-7.mol
更新日期 2023/03/20 15:41:25
315703-52-7 結(jié)構式 315703-52-7 結(jié)構式

基本信息

中文別名
化合物JK184
HEDGEHOG(HH)抑制劑(JK184)
N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
N-(4-乙氧苯基)-4-(2-甲基咪唑并-[1,2-A]吡啶-3-基)噻唑-2-胺
英文別名
JK 184
CS-2369
JK184 (JK-184
Hh Signaling Antagonist VII
Hh Signaling Antagonist VII, JK184
JK 184
JK-184
HH SIGNALING ANTAGONIST VII
Hh Signaling Antagonist VII, JK184 - CAS 315703-52-7 - Calbiochem
N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-thiazolamine
N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-amine
2-ThiazolaMine, N-(4-ethoxyphenyl)-4-(2-MethyliMidazo[1,2-a]pyridin-3-yl)-
所屬類別
生物化工:生化試劑

物理化學性質(zhì)

儲存條件Keep in dark place,Inert atmosphere,2-8°C
溶解度二甲基亞砜:≥20mg/mL
形態(tài)粉末
顏色灰白色至淺棕色

安全數(shù)據(jù)

危險性符號(GHS)GHS hazard pictogramsGHS hazard pictograms
GHS05,GHS07
警示詞危險
危險性描述H302-H318
危險品標志Xn
危險類別碼22-41
安全說明26-36
WGK Germany3
N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺價格(試劑級)
報價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2024/11/08HY-13307N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
JK184
315703-52-75 mg450元
2024/11/08HY-13307N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
JK184
315703-52-710mM * 1mLin DMSO495元
2024/11/08HY-13307N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
JK184
315703-52-710mg750元

常見問題列表

生物活性
JK184抑制Hedgehog信號通路中的Gli,在哺乳動物細胞中IC50為30 nM。
靶點
TargetValue
Gli
()
體外研究

JK184 is designed to antagonize Hh signaling by inhibiting glioma (Gli)-dependent transcriptional activity in a dose dependent manner. JK184 significantly inhibitts proliferation of HUVECs with IC 50 of 6.3 μg/mL after three days incubation. To evaluate anti-tumor effect of JK184, MTT assay is conducted in Panc-1 and BxPC-3 cells after administration with indicated concentrations of compounds, half maximal inhibitory concentration (IC 50 ) of JK184 (23.7 ng/mL in anc-1 and 34.3 ng/mL in BxPC-3). Claudin-low cell lines are more sensitive to JK184 treatment than are MCF10a, MTSV1-7, or HMLE-shGFP and HMLE-pBP cells, and JK184 induced a dose-dependent decrease in glioma-associated oncogene homolog 1 ( GLI1 ) transcript and protein levels in these cells. Treatment with the IC 50 dose of JK184 enhances the proportion of HMLE-shEcad cells that stained with Annexin-V, but are negative for propidium iodide (PI) (P<0.0001, t test).

體內(nèi)研究

JK184 (5 mg/kg, injected intravenously) exhibits good anti-proliferative activity in subcutaneous Panc-1 and BxPC-3 tumor models, and is a good candidate as antitumor drug targeted Hh signaling. However, JK184 has a poor pharmacokinetic profile and bioavailability.

"315703-52-7" 相關產(chǎn)品信息
123-39-7 103-70-8 101-54-2